Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Stock Forecast

Stock Price Forecast

The 21 analysts that cover Vertex Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $496.76, which forecasts a 27.13% increase in the stock price over the next year. The lowest target is $405 and the highest is $575.

Price Target: $496.76 (+27.13%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$405	$496.76	$490	$575
Change	+3.64%	+27.13%	+25.40%	+47.15%

Analyst Ratings

The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	10	10	10	9	8	8
Buy	5	6	6	6	6	6
Hold	10	10	11	11	11	10
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	25	26	27	26	25	24

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Hold Maintains $424 → $411	Hold	Maintains	$424 → $411	+5.18%	Aug 6, 2025
Debjit Chattopadhyay Guggenheim	Guggenheim	Strong Buy Maintains $558 → $546	Strong Buy	Maintains	$558 → $546	+39.73%	Aug 6, 2025
Mohit Bansal Wells Fargo	Wells Fargo	Hold → Buy Upgrades $460	Hold → Buy	Upgrades	$460	+17.72%	Aug 6, 2025
Joon Lee Truist Securities	Truist Securities	Strong Buy Maintains $520 → $490	Strong Buy	Maintains	$520 → $490	+25.40%	Aug 5, 2025
Greg Harrison Scotiabank	Scotiabank	Hold Maintains $442 → $438	Hold	Maintains	$442 → $438	+12.09%	Aug 5, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

12.17B

Increased by 10.40%

from 11.02B

Revenue Next Year

13.46B

Increased by 10.63%

from 12.17B

EPS This Year

18.30

from -2.08

EPS Next Year

21.10

Increased by 15.30%

from 18.30

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	6.21B	7.57B	8.93B	9.87B	11.02B	12.17B	13.46B	14.72B
Revenue Growth	49.08%	22.06%	17.91%	10.51%	11.66%	10.40%	10.63%	9.37%
EPS	10.29	9.01	12.82	13.89	-2.08	18.30	21.10	23.41
EPS Growth	128.16%	-12.44%	42.29%	8.35%	-	-	15.30%	10.93%
Forward PE	-	-	-	-	-	21.35	18.52	16.69
No. Analysts	-	-	-	-	-	37	35	26

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2029
High	12.9B	15.7B	17.7B
Avg	12.2B	13.5B	14.7B
Low	11.5B	11.7B	11.6B

Revenue Growth

Revenue Growth	2025	2026	2027	2029
High	16.7%	29.1%	31.6%
Avg	10.4%	10.6%	9.4%
Low	4.5%	-3.8%	-13.9%

EPS Forecast

EPS	2025	2026	2027	2029
High	19.73	28.05	33.75
Avg	18.30	21.10	23.41
Low	16.56	17.36	18.78

EPS Growth

EPS Growth	2025	2026	2027	2029
High	-	53.2%	59.9%
Avg	-	15.3%	10.9%
Low	-	-5.2%	-11.0%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.